Shionogi redasemtide (S-005151) o'tkir ishemik insultni (AIS) davolashda 2-bosqich klinik muvaffaqiyati!

Yaponiya farmatsevtika kompaniyasi Shionogi yaqinda o'tkir ishemik insult (AIS) bilan og'rigan bemorlarda regeneratsiyani qo'zg'atuvchi S-005151 (redasemtide) preparatining 2-bosqich klinik sinovining ijobiy natijalarini e'lon qildi. Redasemtid - regeneratsiyani qo'zg'atuvchi dori bo'lib, tirik hujayralar o'rniga preparatni qo'llash orqali shikastlanish yoki kasallik tufayli shikastlangan to'qimalarni tiklaydi.

This is a randomized, double-blind, placebo-controlled clinical trial in patients 4.5 to 24 hours after the onset of AIS who are not candidates for revascularization therapy (thrombolysis or mechanical thrombectomy [MT]). The primary objective of the trial was to examine the efficacy and safety of redasemtide. The primary endpoint was efficacy as assessed by the Modified Rankin Scale (mRS) 90 days after treatment. The Modified Rankin Scale is a scale commonly used to measure disability or dependence in daily activities in patients with stroke or other neuropathy.

Based on the positive results of the aforementioned Phase 2 clinical trial, Shionogi will prepare for the transition of redasemtide to a global Phase 3 clinical trial for the treatment of acute ischemic stroke (AIS).

redasemtide belongs to an innovative new class of drugs called "Regeneration-inducing Medicine" that induce tissue damage due to injury or disease by maximizing the body's inherent ability to repair tissue and functional regeneration of organs. Redasemtide accelerates the reconstruction of damaged tissue by mobilizing bone marrow-derived mesenchymal stem cells into peripheral blood, increasing the number of mesenchymal stem cells in the blood circulation and accumulating them in damaged tissues.

Hozirgi vaqtda Shionogi distrofik epidermoliz bullosa, surunkali jigar kasalligi, tizza osteoartriti, kardiyomiyopatiya va o'tkir ishemik insultda (AIS) redasemtid rivojlanishini rivojlantirmoqda. Redasemtide ilgari Osaka universiteti va boshqa muassasalarda 2-bosqich klinik tadqiqotlarida distrofik epidermoliz bullosa (DEB) samaradorligini ko'rsatdi.